TruSight Oncology 500 enables comprehensive genomic profiling (CGP) of solid tumors. As CGP indication and utilization grows, distributed solutions require more sensitive profiling from FFPE, faster, streamlined workflows and comprehensive content inclusive of IO biomarkers and HRD. Hear from experts about Illumina’s efforts to further develop these aspects and democratize NGS biomarker profiling.
